Evidence map›Paper›PMID 41963642›Full record

ArticleEMBO molecular medicine2026

SHP-1 agonist SC-43 limits methicillin-resistant Staphylococcus aureus infection through inhibition of heme biosynthesis.

Yini Huang, Yan Ye, Xinmei Zhu, Dengpan Liang, Ruiqin Cui, Xiaopeng Yuan, Xitao Li, Quanming Zou, Haibo Li, Wei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yini Huang *Department of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Yan Ye *National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Xinmei ZhuDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Dengpan LiangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Ruiqin CuiDepartment of Pharmacy, Shenzhen People's Hospital (The First Affiliated Hospital, School of Medicine, Southern University of Science and Technology), Shenzhen, 518020, China.
Xiaopeng YuanDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Xitao LiSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China. lixt78@mail.sysu.edu.cn.
Quanming ZouNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, China. qmzou@tmmu.edu.cn.
Haibo LiNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, China. lihaibo@tmmu.edu.cn.ORCID 0000-0003-4014-3770
Wei HuangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China. weihuang@mail.sustech.edu.cn.ORCID 0000-0002-8569-5184

Funding

Fundamental research funds for the central universities 24qnpy061Guangdong provincial clinical research center for laboratory medicine 2023B110008MOST | National Natural Science Foundation of China (NSFC) 82173859| Natural Science Foundation of Shenzhen Municipality (Shenzhen Natural Science Foundation) GJHZ20220913142800001,SYSPG20241211173920041,ZDSYS20111002| Natural Science Foundation of Shenzhen Municipality (Shenzhen Natural Science Foundation) ZDSYS20111002Shenzhen clinical research center for respiratory disease LCYSSQ20220823091203007Shenzhen people's hospital physician scientist training "Five Three Program" SYWGSCGZH202401
6 · The paper itself

Abstract

The limitations of existing drugs and the development of drug resistance make it urgent to develop new drugs against methicillin-resistant Staphylococcus aureus (MRSA). The re-development of the antibacterial activity of drugs that have already been proven safe for human use is an effective way. In this study, we discovered that the Src homology region 2 domain-containing phosphatase-1 (SHP-1) agonist SC-43, exhibits potent activity against Gram-positive bacteria, including MRSA. The mode of action studies revealed that SC-43 inhibits the key enzyme coproporphyrin ferrochelatase (CpfC) of the coproporphyrin-dependent (CPD) heme synthesis pathway and interferes with the bacterial porphyrin metabolism. The determination of the structure of CpfC derived from S. aureus (SA

Indexed as

Anti-Bacterial AgentsHemeMethicillin-Resistant Staphylococcus aureusProtein Tyrosine Phosphatase, Non-Receptor Type 6Staphylococcal InfectionsAnimalsFerrochelataseHumansMiceAnti-Bacterial AgentsFerrochelataseHemeProtein Tyrosine Phosphatase, Non-Receptor Type 6

Identifiers

PMID41963642
PMCPMC13179323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.